Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines

Vaccine
Jennifer MullinQibo Zhang

Abstract

Recent efforts have been focused on the development of vaccines that could induce broad immunity against influenza virus, either through T cell responses to conserved internal antigens or B cell response to cross-reactive haemagglutinin (HA). We studied the capacity of Modified Vaccinia Ankara (MVA)-vectored influenza vaccines to induce cross-reactive immunity to influenza virus in human nasopharynx-associated lymphoid tissue (NALT) in vitro. Adenotonsillar cells were isolated and stimulated with MVA vaccines expressing either conserved nucleoprotein (NP) and matrix protein 1 (M1) (MVA-NP-M1) or pandemic H1N1 HA (MVA-pdmH1HA). The MVA vaccine uptake and expression, and T and B cell responses were analyzed. MVA-vectored vaccines were highly efficient infecting NALT and vaccine antigens were highly expressed by B cells. MVA-NP-M1 elicited T cell response with greater numbers of IFNγ-producing CD4+ T cells and tissue-resident memory T cells than controls. MVA-pdmH1HA induced cross-reactive anti-HA antibodies to a number of influenza subtypes, in an age-dependent manner. The cross-reactive antibodies include anti-avian H5N1 and mainly target HA2 domain. MVA vaccines are efficient in infecting NALT and the vaccine antigen is highly ...Continue Reading

References

Nov 24, 1999·Immunological Reviews·J SchneiderA V Hill
Nov 6, 2004·The Journal of Infectious Diseases·Terry GuthrieNeil A Williams
Jun 5, 2007·Vaccine·Noelle-Angelique M MolinariCarolyn B Bridges
Feb 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Max CorbettAlain Le Pape
Feb 24, 2009·Nature Structural & Molecular Biology·Jianhua SuiWayne A Marasco
Mar 3, 2009·Science·Damian C EkiertIan A Wilson
May 1, 2007·Influenza and Other Respiratory Viruses·Nigel J TempertonRobin A Weiss
Aug 20, 2010·The Journal of General Virology·Joost H C M KreijtzGuus F Rimmelzwaan
Dec 15, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tamara K BerthoudSarah C Gilbert
Jan 12, 2011·The Journal of Experimental Medicine·Jens WrammertPatrick C Wilson
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Natalie PicaPeter Palese
May 23, 2012·Proceedings of the National Academy of Sciences of the United States of America·Gui-Mei LiRafi Ahmed
Jan 1, 2012·Journal of Molecular and Genetic Medicine : an International Journal of Biomedical Research·Francesca FerraraNigel J Temperton
Jan 1, 2012·Journal of Molecular and Genetic Medicine : an International Journal of Biomedical Research·Eleonora MolestiNigel Temperton
Nov 27, 2014·The Journal of Infectious Diseases·Kristin G-I MohnRebecca J Cox
Dec 20, 2014·Immunity·Jason M Schenkel, David Masopust

❮ Previous
Next ❯

Citations

Jan 27, 2018·Virology Journal·Giuseppe A SauttoTed M Ross
Feb 16, 2020·Nature Reviews. Drug Discovery·Chih-Jen WeiGary J Nabel
Apr 30, 2021·Biotechnology and Bioengineering·Sofia B CarvalhoRicardo J S Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.